Captor Therapeutics Spolka Akcyjna
CTX
Rank in Stocks
#20327
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the... Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Share Price
$13.71
Last synced: 2026-11-09
Market Cap
$86.85M
Change (1 day)
0.13%
Change (1 year)
4.77%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Captor Therapeutics Spolka Akcyjna (CTX)
Category
Healthcare
Operating Margin for Captor Therapeutics Spolka Akcyjna (CTX)
Operating Margin as of November 2026 TTM: -2,534.30%
According to Captor Therapeutics Spolka Akcyjna's latest financial reports, its current operating margin (TTM) is -2,534.30%. At the end of 2025 the company had an operating margin of -1,141.78%.
Operating Margin history for Captor Therapeutics Spolka Akcyjna from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2,534.30% | 121.96% |
| 2025 | -1,141.78% | 303.68% |
| 2024 | -282.84% | -48.86% |
| 2023 | -553.11% | 32.04% |
| 2022 | -418.91% | -47.34% |
| 2021 | -795.48% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -25,812.50% | 91,890.38% |
| 2017 | -28.06% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.02% |
US
|
|
| -149.01% | -99.94% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Captor Therapeutics Spolka Akcyjna's operating margin
What is Captor Therapeutics Spolka Akcyjna's operating margin?
Captor Therapeutics Spolka Akcyjna's operating margin is -2,534.30%, as of Nov 2026.
What was Captor Therapeutics Spolka Akcyjna's operating margin in 2025?
In 2025, Captor Therapeutics Spolka Akcyjna's operating margin was -1,141.78%, compared with -282.84% in 2024.
How has Captor Therapeutics Spolka Akcyjna's operating margin changed since 2020?
From 2020 to 2025, Captor Therapeutics Spolka Akcyjna's operating margin was highest in 2020 (0.00%) and lowest in 2025 (-1,141.78%).
How does Captor Therapeutics Spolka Akcyjna's operating margin compare with similar companies?
Captor Therapeutics Spolka Akcyjna's operating margin (-2,534.30%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.